Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

91
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Diagnostic Value of Routine Delayed Pelvic Imaging for Patients with Biochemical Recurrence of Prostate Cancer Undergoing <sup>68</sup>Ga-PSMA PET/CT.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

HER2-targeted PET/CT in breast cancer: a systematic review of lesion-level concordance with pathology.

European journal of radiology·2026
Same author

Persistent PSMA Expression at a Subdural Hematoma Following Middle Meningeal Artery Embolization.

Clinical nuclear medicine·2026
Same author

Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.

Insights into imaging·2026
Same author

Reply to "Critical Evaluation of HER2 PET Imaging in Metastatic Breast Cancer: Addressing Key Challenges and Future Directions" and "The Role of HER2 PET in Treatment of Breast Cancer".

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2025

Related Experiment Video

Updated: Jun 27, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

415

Hepatic PSMA-Avid Postradiation Inflammation.

Patrick Silveira1, Aria Razmaria, Randy Yeh

  • 1From the Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

Clinical Nuclear Medicine
|May 2, 2024
PubMed
Summary
This summary is machine-generated.

Gallium-68 PSMA PET/CT imaging identified metastatic prostate cancer in bone, liver, and nodes. This imaging is crucial for determining patient eligibility for Lutetium-177 PSMA therapy.

More Related Videos

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Related Experiment Videos

Last Updated: Jun 27, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

415
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

9.9K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.1K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceuticals

Background:

  • Advanced prostate cancer requires effective imaging for treatment planning.
  • Gallium-68 PSMA PET/CT (68Ga-PSMA PET/CT) is a key diagnostic tool.
  • Eligibility for Lutetium-177 PSMA (177Lu-PSMA) therapy necessitates precise staging.

Observation:

  • A 62-year-old male patient presented with de novo metastatic prostate cancer.
  • The patient had undergone prior therapies, including radiation to the T12-L2 vertebrae.
  • 68Ga-PSMA PET/CT was performed to assess metastatic burden and treatment candidacy.

Findings:

  • The imaging revealed significant tracer uptake in bone, liver, and lymph node metastases.
  • Specific regional tracer avidity was noted in the left hepatic lobe, possibly related to prior radiation.
  • Absence of FDG avidity in the hepatic lesion suggested an inflammatory, rather than purely metastatic, process.

Implications:

  • 68Ga-PSMA PET/CT accurately identifies metastatic prostate cancer lesions.
  • This imaging modality is vital for selecting patients eligible for 177Lu-PSMA therapy.
  • Understanding imaging findings in the context of prior treatments is crucial for accurate interpretation.